WHAT EACH PART DID IN STUDIES
What research says each KLOW peptide part does
The four parts were studied one at a time. See what changed in people, animals, or cells, and what those findings can’t tell you.
What separate studies of the four ingredients found
There isn’t one group of KLOW studies. Researchers tested KPV, GHK-Cu, BPC-157, and the full protein tied to TB-500 in separate work.
The four may affect different parts of tissue repair. Researchers haven’t put that idea to a fair test in one vial.
The sections below say who or what was studied and what changed. Each result belongs only to the ingredient actually used.
KLOW hasn’t been compared with one ingredient, fewer ingredients, or placebo in animals or people. I'd call a full-blend claim a guess until that test is done.
For your visit, ask which paper best matches your concern. Then ask what still isn’t known for someone like you.
You can bring the separate studies up with your clinician. Ask what it means for you and what it can’t settle.
What KPV did to swelling in the bowel
KPV is three linked building blocks cut from a 13-residue hormone, meaning a hormone made from linked protein building blocks. A hormone is a protein that carries a message in the body.
A 2008 paper [3] tested KPV in human gut and immune-system cells in a dish. It also tested mice with colitis.
KPV lowered signs the cells use when swelling starts. The paper’s lab signs numbered 6 and 8 also fell. In mice, drinking water with 100 micromoles per liter made the bowel illness less severe.
A micromole per liter is a lab measure of how much was in the water. It isn’t a human dose.
Sore gut cells pulled KPV through a doorway in the cell wall. One lab check measured about 160 micromoles per liter passing through that doorway.
That number only describes the dish test. It can’t tell you how KPV or KLOW would act in your bowel.
A 2024 paper gave mice KPV with FK506, a drug that calms the immune system [8]. Tiny drops carried both drugs to the gut.
The pair helped short-term and long-term colitis more than either drug alone. A 2010 mouse study tested an older way to carry medicine to the colon [9].
Together, the papers support more bowel research. They don’t show that KLOW helps your gut.
I'd ask your doctor what human proof exists. The answer may be that none does yet.
For your visit, ask how the bowel findings apply to you. Your clinician can say what it can’t prove.
What GHK-Cu did in skin, bowel, and hair studies
GHK-Cu is a short peptide that carries copper. It is about 62.5% of the usual 80 mg KLOW vial.
Loren Pickart first took GHK from human blood in 1973. Most work in people has dealt with skin.
A 2015 review [4] found that GHK-Cu helped skin make collagen. Collagen is the firm protein that gives skin support.
Tests found more collagen in 70% of women given GHK-Cu. The rates were 50% with vitamin C and 40% with retinoic acid.
The same work saw changes in loose skin, fine lines, and wrinkle depth. Those are changes a person might notice.
Blood GHK fell from about 200 nanograms per milliliter at age 20 to about 80 nanograms per milliliter by age 60. That doesn’t give a treatment goal for you late in life.
A 2018 dish study [5] used 1–10 nanomoles per liter, a tiny lab amount. About 31.2% of the cell instructions changed by at least 50%.
In one group, 41 instructions became more active and 1 became less active. The table described 1 fall in activity. The study didn’t show if this would help or harm a person.
A larger claim about changed instructions is often repeated. The claim says roughly 4,000, but the table covers about 2,100 that make proteins. That larger 4,000 claim isn’t sound.
Newer work includes a 2025 bowel study [11] and a 2025 skin review [12]. A 1991 study found more hair growth in an ordinary strain of lab mice [15].
I'd ask which result the clinic expects you to notice. A change in cells isn’t the same as better skin or health.
Your question about the skin findings deserves a clear answer. Don’t leave until you know what remains unproved.
What BPC-157 did in rat tendon studies
BPC-157 is a man-made peptide with a 15-amino-acid chain, meaning that many linked protein building blocks. It was first tied to a protein in stomach juice.
Animal work suggests BPC-157 may help new blood reach hurt tissue. That might aid repair, but it might matter in cancer too.
A 2003 rat study [2] used 10 micrograms, 10 nanograms, or 10 picograms. The rats had fully cut Achilles tendons.
BPC-157 improved tendon strength, use, and appearance under a microscope. A second check also looked inside the healing tissue.
Only BPC-157 was used in those tests. Tendon cells also grew in a dish.
A 2006 follow-up [10] found better healing where tendon meets bone. The rats also had less harm from a steroid; source 2 is the earlier tendon paper. That source 2 used the same tendon peptide.
A 2025 safety test [6] gave two adults 10 mg on day one and 20 mg on day two. Neither had a reported bad event or clear change in safety blood tests.
Two people can’t settle safety. A 2026 review [7] gathered past work on pain and tissue repair.
The FDA has reviewed BPC-157 as a substance that may pose safety risks when mixed by a pharmacy. That review is not approval or proof of safe use.
If your tendon is sore, ask how a fully cut rat tendon compares with yours. I'd also ask what human work supports the clinic’s claim.
You can bring the tendon findings up with your clinician. Ask what it means for you and what it can’t settle.
What TB-500 itself still hasn’t proved
TB-500 is cut from a full protein called thymosin beta-4. The full 43-amino-acid protein is called thymosin beta-4; the short piece is much smaller.
That difference matters because most strong findings belong to the full protein. A 1999 rat study [1] tested deep skin wounds.
Skin closing rose 42% at 4 days and as much as 61% at 7 days, compared with salt water. Wounds also shrank at least 11% more by day 7.
The wounds had more collagen and new blood vessels. Just 10 picograms also made skin cells move 2–3-fold, or two to three times as far in a dish.
A 2024 lung study [13] and two 2026 discussions [14] also dealt with the full protein. The 2026 review [14] found hopeful animal work, little sound human safety work, and no approval for TB-500.
World anti-doping agency is what WADA means. It bars TB-500 and thymosin beta-4. Because KLOW contains TB-500, athletes can’t use the whole mix.
When you want a plain answer, ask which form was tested. I'd also ask what proof comes from people, not rats or cells.
For your visit, ask how the wound findings apply to you. Your clinician can say what it can’t prove.